| P50 | author | Osamu Ukimura | Q88616646 |
| P2093 | author name string | Fumiya Hongo | |
| | Tetsuya Taguchi | |
| | Shigeru Hirano | |
| | Masayoshi Inoue | |
| | Yoshito Itoh | |
| | Koichi Takayama | |
| | Toshiyuki Kosuga | |
| | Hirotaka Konishi | |
| | Takeshi Ishikawa | |
| | Junji Uchino | |
| | Satoshi Komori | |
| | Akihito Arai | |
| | Hiroaki Tsunezuka | |
| | Jun Asai | |
| | Tomoki Sakakida | |
| | Yusuke Tabuchi | |
| P2860 | cites work | Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors | Q92594192 |
| | A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial | Q92710266 |
| | Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies | Q92853001 |
| | Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis | Q27022482 |
| | A new method of classifying prognostic comorbidity in longitudinal studies: development and validation | Q29547376 |
| | Toxicity and response criteria of the Eastern Cooperative Oncology Group | Q29619399 |
| | Nivolumab in previously untreated melanoma without BRAF mutation | Q29620688 |
| | Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 |
| | PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma | Q29620878 |
| | Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 |
| | Frailty and inflammatory markers in older adults with cancer | Q33563551 |
| | CD28(-) T cells: their role in the age-associated decline of immune function | Q33572405 |
| | Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis | Q33762053 |
| | The prevalence and outcomes of frailty in older cancer patients: a systematic review | Q35430157 |
| | T cell subset-specific susceptibility to aging. | Q36731766 |
| | Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study | Q36760924 |
| | International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer | Q36925135 |
| | Optimization of immunotherapy in elderly cancer patients | Q37650300 |
| | Preoperative prognostic nutritional index is a powerful predictor of prognosis in patients with stage III ovarian cancer | Q38607564 |
| | Immune Checkpoint Inhibitors in Older Adults | Q38861565 |
| | Immunotherapy comes of age: Immune aging & checkpoint inhibitors | Q38949503 |
| | Increased neutrophil-to-lymphocyte ratio is a novel marker for nutrition, inflammation and chemotherapy outcome in patients with locally advanced and metastatic esophageal squamous cell carcinoma | Q40991226 |
| | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | Q41316099 |
| | Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck | Q43164702 |
| | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Q47745009 |
| | FRAIL Questionnaire Screening Tool and Short-Term Outcomes in Geriatric Fracture Patients. | Q50230754 |
| | Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function. | Q51032192 |
| | The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population | Q56890191 |
| | Prognostic value of prognostic nutritional index in lung cancer: a meta-analysis | Q58770858 |
| | [Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients] | Q70507813 |
| | Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC | Q89506800 |
| | Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma | Q91126135 |
| | Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer | Q91276123 |
| | From clinical trials to real-world practice: Immune checkpoint inhibitors in older adults | Q91466008 |
| | Immune checkpoint inhibitors in older adults with melanoma or cutaneous malignancies: The Wilmot Cancer Institute experience | Q91862806 |
| | Clinical significance of prognostic nutritional index (PNI) in malignant melanoma | Q91905416 |
| | Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer | Q91984210 |
| | Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer | Q92560221 |
| P433 | issue | 4 | |
| P304 | page(s) | 14 | |
| P577 | publication date | 2020-07-15 | |
| P1433 | published in | Oncology Letters | Q20640514 |
| P1476 | title | Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies | |
| P478 | volume | 20 | |